We provide you with 20 years of free, institutional-grade data for FULC stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of FULC. Explore the full financial landscape of FULC stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Tourangeau Greg | Sale | -4,884 | $11.72 | $57,219 | 2024-03-08 |
| Sapir Alex | Open Market Purchase | 43,360 | $11.35 | 2024-03-05 | |
| Tourangeau Greg | Sale | -210 | $3.31 | $695 | 2023-05-11 |
| RA CAPITAL MANAGEMENT, L.P. | Open Market Purchase | 1,923,076 | $13 | 2023-01-24 | |
| Gould Robert J | Sale | -6,766 | $15 | $101,490 | 2023-01-13 |
| RA CAPITAL MANAGEMENT, L.P. | Open Market Purchase | 180,703 | $7.03 | 2023-01-06 | |
| RA CAPITAL MANAGEMENT, L.P. | Open Market Purchase | 4,089 | $5.99 | 2022-12-29 | |
| RA CAPITAL MANAGEMENT, L.P. | Open Market Purchase | 98,787 | $5.9 | 2022-12-21 | |
| RA CAPITAL MANAGEMENT, L.P. | Open Market Purchase | 2,403,049 | $5.46 | 2022-12-16 | |
| Gould Robert J | Sale | -71,435 | $8.09 | $577,895 | 2022-06-08 |
| Gould Robert J | Derivatives Exercise | 71,435 | 2022-06-08 | ||
| Gould Robert J | Sale | -66,622 | $7.92 | $527,586 | 2022-06-06 |
| Gould Robert J | Derivatives Exercise | 66,622 | 2022-06-06 | ||
| Tourangeau Greg | Grant, award...etc | 3,250 | 2022-05-10 | ||
| Gould Robert J | Sale | -5,631 | $24.02 | $135,228 | 2022-04-11 |
| Gould Robert J | Derivatives Exercise | 5,631 | 2022-04-11 | ||
| Gould Robert J | Sale | -94,251 | $24.03 | $2,264,823 | 2022-04-05 |
| Gould Robert J | Derivatives Exercise | 94,251 | 2022-04-05 | ||
| Tourangeau Greg | Initial | 2022-03-14 | |||
| Moxham Christopher | Sale | -51,785 | $17 | $880,345 | 2021-08-12 |
| Moxham Christopher | Derivatives Exercise | 51,785 | 2021-08-12 | ||
| Stuart Bryan | Sale | -60,000 | $17.5 | $1,050,000 | 2021-08-12 |
| Stuart Bryan | Derivatives Exercise | 60,000 | 2021-08-12 | ||
| GERAGHTY JAMES A | Open Market Purchase | 10,000 | $9.16 | 2021-06-29 | |
| Oltmans Curtis Gale | Open Market Purchase | 1,088 | $9.01 | 2021-06-29 | |
| Morabito Christopher | Open Market Purchase | 1,100 | $9.16 | 2021-06-29 | |
| Thomson Peter G. | Open Market Purchase | 2,300 | $9 | 2021-06-29 | |
| Gould Robert J | Sale | -10,000 | $12.13 | $121,347 | 2021-03-17 |
| Thomson Peter G. | Sale | -5,000 | $14.72 | $73,582 | 2021-02-24 |
| Thomson Peter G. | Derivatives Exercise | 5,000 | 2021-02-24 | ||
| Gould Robert J | Sale | -8,215 | $14.19 | $116,570 | 2021-02-18 |
The information provided in this report about FULC stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Fulcrum Therapeutics, Inc(NASDAQ:FULC) 
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is i...
Website: http://www.fulcrumtx.com
Founded: 2015
Full Time Employees: 73
CEO: Robert J. Gould
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends